Ignite Creation Date:
2025-12-26 @ 10:36 AM
Ignite Modification Date:
2026-03-04 @ 3:43 PM
Study NCT ID:
NCT00507728
Status:
COMPLETED
Last Update Posted:
2021-05-06
First Post:
2007-07-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pharmacogenetics, Emotional Reactivity and Smoking
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014029', 'term': 'Tobacco Use Disorder'}, {'id': 'D016540', 'term': 'Smoking Cessation'}, {'id': 'D012907', 'term': 'Smoking'}], 'ancestors': [{'id': 'D019966', 'term': 'Substance-Related Disorders'}, {'id': 'D064419', 'term': 'Chemically-Induced Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D015438', 'term': 'Health Behavior'}, {'id': 'D001519', 'term': 'Behavior'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D016642', 'term': 'Bupropion'}, {'id': 'D000068580', 'term': 'Varenicline'}], 'ancestors': [{'id': 'D011427', 'term': 'Propiophenones'}, {'id': 'D007659', 'term': 'Ketones'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001552', 'term': 'Benzazepines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011810', 'term': 'Quinoxalines'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'pcinciri@mdanderson.org', 'phone': '(713) 745-1868', 'title': 'Paul M Cinciripini, MD, Chair, Behavioral Science', 'organization': 'UT MD Anderson Cancer Center'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'Baseline, up to 8 months', 'eventGroups': [{'id': 'EG000', 'title': 'Varenicline', 'description': 'Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).\n\nVarenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)', 'otherNumAtRisk': 75, 'deathsNumAtRisk': 75, 'otherNumAffected': 63, 'seriousNumAtRisk': 75, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG001', 'title': 'Bupropion', 'description': 'Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).\n\nBupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)', 'otherNumAtRisk': 89, 'deathsNumAtRisk': 89, 'otherNumAffected': 69, 'seriousNumAtRisk': 89, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG002', 'title': 'Placebo', 'description': 'Placebo by mouth for 12 weeks.\n\nPlacebo: Placebo by mouth for 12 weeks.', 'otherNumAtRisk': 90, 'deathsNumAtRisk': 90, 'otherNumAffected': 66, 'seriousNumAtRisk': 90, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'ABSCESS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'ACCIDENTAL INJURY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'APPETITE DECREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'APPETITE INCREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 5}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'ASTHMA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Abnormal Dreams', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 7}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Allergic reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Allergy, Seasonal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Anxiety Symptoms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 13}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'BLOOD IN STOOL', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'BRONCHITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'BRUISE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 4}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blurred vision', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 2}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Body odor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Cerebrospinal fluid..', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Chest pain - cardiac', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 11}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Chest wall pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 4}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'DIABETES MELLITUS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 10}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 12}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Disturbance in attention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 12}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Drowsiness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 5}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 7}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dysphagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Eczema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Edema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 5}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Elevated mood', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Emotional liability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 4}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Eye irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 2}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 9}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Flatulence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Flushing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Glucose intolerance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 13}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 11}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hemorrhoids', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Herniated Disc', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypercholesterolemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypertriglyceridemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypoglycemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypothyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Increased Coughing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 4}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 16}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 26}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 13}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Irritability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 14}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 13}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Kidney Stones', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Libido decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Mucositis oral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 12}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 17}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 8}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Neck pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'PARESTHESIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'PNEUMONIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 6}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pelvic pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Reduced inhibition', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Restlessness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 5}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 26}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 23}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'SWEATING INCREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Sensory disturbance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Shortness of Breath', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 11}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Sore throat', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 9}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Suicidal ideation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Surgical and medical', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'TASTE PERVERSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 6}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'TREMOR', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Tachycardia/Palpita..', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Tinnitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'URINARY INCONTINENCE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Urinary frequency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Urine abnormality', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Weight gain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Weight loss', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Shortness of Breath', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Eczema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Urinary Incontinence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Chest pain - cardiac', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Increased Coughing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 89, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 90, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '1'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Emotional Reactivity By Pharmacotherapy', 'denoms': [{'units': 'Participants', 'counts': [{'value': '78', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '90', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline', 'description': 'Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).\n\nVarenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)'}, {'id': 'OG001', 'title': 'Bupropion', 'description': 'Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).\n\nBupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Placebo by mouth for 12 weeks.\n\nPlacebo: Placebo by mouth for 12 weeks.'}], 'classes': [{'title': 'Emotional Reactivity (ORB) to Cigarette Stimuli', 'categories': [{'measurements': [{'value': '66.6', 'groupId': 'OG000', 'lowerLimit': '62.3', 'upperLimit': '71.1'}, {'value': '64.7', 'groupId': 'OG001', 'lowerLimit': '60.9', 'upperLimit': '68.5'}, {'value': '65.6', 'groupId': 'OG002', 'lowerLimit': '61.5', 'upperLimit': '69.7'}]}]}, {'title': 'Emotional Reactivity (ORB) to Negative Stimuli', 'categories': [{'measurements': [{'value': '70.9', 'groupId': 'OG000', 'lowerLimit': '66.4', 'upperLimit': '75.4'}, {'value': '73.1', 'groupId': 'OG001', 'lowerLimit': '69.2', 'upperLimit': '76.9'}, {'value': '65.6', 'groupId': 'OG002', 'lowerLimit': '61.5', 'upperLimit': '69.7'}]}]}, {'title': 'Emotional Reactivity (ORB) to Positive Stimuli', 'categories': [{'measurements': [{'value': '66.7', 'groupId': 'OG000', 'lowerLimit': '62.5', 'upperLimit': '70.9'}, {'value': '65.4', 'groupId': 'OG001', 'lowerLimit': '61.8', 'upperLimit': '68.9'}, {'value': '64.7', 'groupId': 'OG002', 'lowerLimit': '60.8', 'upperLimit': '68.6'}]}]}, {'title': 'Emotional Reactivity (ORB) to Neutral Stimuli', 'categories': [{'measurements': [{'value': '59.6', 'groupId': 'OG000', 'lowerLimit': '45.2', 'upperLimit': '74.1'}, {'value': '64.9', 'groupId': 'OG001', 'lowerLimit': '52.7', 'upperLimit': '77.2'}, {'value': '72.5', 'groupId': 'OG002', 'lowerLimit': '59.3', 'upperLimit': '85.7'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 1 month', 'description': 'Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.', 'unitOfMeasure': 'microvolts', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Emotional Reactivity By Pharmacotherapy Moderated by DRD2 A1 Allele', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline w/o DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group not carrying the DRD2 A1 allele'}, {'id': 'OG001', 'title': 'Varenicline With DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group carrying the DRD2 A1 allele'}, {'id': 'OG002', 'title': 'Bupropion w/o DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group not carrying the DRD2 A1 allele'}, {'id': 'OG003', 'title': 'Bupropion With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}, {'id': 'OG004', 'title': 'Placebo w/o DRD2 A1 Allele', 'description': 'Subjects in the Placebo group not carrying the DRD2 A1 allele'}, {'id': 'OG005', 'title': 'Placebo With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}], 'classes': [{'title': 'Emotional Reactivity (ORB) to Cigarette Stimuli', 'categories': [{'measurements': [{'value': '66.5', 'groupId': 'OG000', 'lowerLimit': '61.1', 'upperLimit': '71.9'}, {'value': '69.9', 'groupId': 'OG001', 'lowerLimit': '62.8', 'upperLimit': '77.0'}, {'value': '66.2', 'groupId': 'OG002', 'lowerLimit': '60.4', 'upperLimit': '72'}, {'value': '66', 'groupId': 'OG003', 'lowerLimit': '60.9', 'upperLimit': '71.2'}, {'value': '67.3', 'groupId': 'OG004', 'lowerLimit': '61.5', 'upperLimit': '73.1'}, {'value': '68.1', 'groupId': 'OG005', 'lowerLimit': '62.2', 'upperLimit': '73.9'}]}]}, {'title': 'Emotional Reactivity (ORB) to Negative Stimuli', 'categories': [{'measurements': [{'value': '70.5', 'groupId': 'OG000', 'lowerLimit': '65', 'upperLimit': '75.9'}, {'value': '75.1', 'groupId': 'OG001', 'lowerLimit': '67.9', 'upperLimit': '82.2'}, {'value': '78.6', 'groupId': 'OG002', 'lowerLimit': '72.8', 'upperLimit': '84.4'}, {'value': '71.3', 'groupId': 'OG003', 'lowerLimit': '66.2', 'upperLimit': '76.5'}, {'value': '74', 'groupId': 'OG004', 'lowerLimit': '68.2', 'upperLimit': '79.7'}, {'value': '68.1', 'groupId': 'OG005', 'lowerLimit': '62.2', 'upperLimit': '73.9'}]}]}, {'title': 'Emotional Reactivity (ORB) to Positive Stimuli', 'categories': [{'measurements': [{'value': '65.5', 'groupId': 'OG000', 'lowerLimit': '60.4', 'upperLimit': '70.6'}, {'value': '72', 'groupId': 'OG001', 'lowerLimit': '65.3', 'upperLimit': '78.7'}, {'value': '71.3', 'groupId': 'OG002', 'lowerLimit': '65.8', 'upperLimit': '76.7'}, {'value': '63.3', 'groupId': 'OG003', 'lowerLimit': '58.4', 'upperLimit': '681.'}, {'value': '68.5', 'groupId': 'OG004', 'lowerLimit': '63.1', 'upperLimit': '74'}, {'value': '63.8', 'groupId': 'OG005', 'lowerLimit': '58.3', 'upperLimit': '69.4'}]}]}, {'title': 'Emotional Reactivity (ORB) to Neutral Stimuli', 'categories': [{'measurements': [{'value': '55.3', 'groupId': 'OG000', 'lowerLimit': '37.4', 'upperLimit': '73.2'}, {'value': '67.2', 'groupId': 'OG001', 'lowerLimit': '43', 'upperLimit': '91.5'}, {'value': '73.9', 'groupId': 'OG002', 'lowerLimit': '54.6', 'upperLimit': '93.1'}, {'value': '61.2', 'groupId': 'OG003', 'lowerLimit': '44', 'upperLimit': '78.3'}, {'value': '79.7', 'groupId': 'OG004', 'lowerLimit': '61', 'upperLimit': '98.5'}, {'value': '67.8', 'groupId': 'OG005', 'lowerLimit': '48.3', 'upperLimit': '87.2'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 1 month', 'description': 'The emotional reactivity (ORB EMG) of smokers during cessation will be moderated by genotype. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.', 'unitOfMeasure': 'microvolts', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': '13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.'}, {'type': 'SECONDARY', 'title': 'Smoking Abstinence at 3 Months', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '90', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline', 'description': 'Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).\n\nVarenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)'}, {'id': 'OG001', 'title': 'Bupropion', 'description': 'Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).\n\nBupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Placebo by mouth for 12 weeks.\n\nPlacebo: Placebo by mouth for 12 weeks.'}], 'classes': [{'title': 'Emotional Reactivity (ORB) to Cigarette Stimuli', 'categories': [{'measurements': [{'value': '-0.003', 'groupId': 'OG000', 'lowerLimit': '-0.0777', 'upperLimit': '0.072'}, {'value': '-0.01', 'groupId': 'OG001', 'lowerLimit': '-0.084', 'upperLimit': '0.065'}, {'value': '-0.008', 'groupId': 'OG002', 'lowerLimit': '-0.096', 'upperLimit': '0.081'}]}]}, {'title': 'Emotional Reactivity (ORB) to Negative Stimuli', 'categories': [{'measurements': [{'value': '-0.004', 'groupId': 'OG000', 'lowerLimit': '-0.081', 'upperLimit': '0.073'}, {'value': '-0.009', 'groupId': 'OG001', 'lowerLimit': '-0.076', 'upperLimit': '0.058'}, {'value': '-0.007', 'groupId': 'OG002', 'lowerLimit': '-0.088', 'upperLimit': '0.073'}]}]}, {'title': 'Emotional Reactivity (ORB) to Positive Stimuli', 'categories': [{'measurements': [{'value': '-0.003', 'groupId': 'OG000', 'lowerLimit': '-0.081', 'upperLimit': '0.076'}, {'value': '-0.01', 'groupId': 'OG001', 'lowerLimit': '-0.084', 'upperLimit': '0.064'}, {'value': '-0.007', 'groupId': 'OG002', 'lowerLimit': '-0.092', 'upperLimit': '0.079'}]}]}, {'title': 'Emotional Reactivity (ORB) to Neutral Stimuli', 'categories': [{'measurements': [{'value': '-0.004', 'groupId': 'OG000', 'lowerLimit': '-0.085', 'upperLimit': '0.076'}, {'value': '-0.008', 'groupId': 'OG001', 'lowerLimit': '-0.084', 'upperLimit': '0.068'}, {'value': '-0.007', 'groupId': 'OG002', 'lowerLimit': '-0.088', 'upperLimit': '0.075'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 3 months', 'description': 'Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.', 'unitOfMeasure': 'probability', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Smoking Abstinence at 3 Months by DRD2 A1 Allele', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline w/o DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group not carrying the DRD2 A1 allele'}, {'id': 'OG001', 'title': 'Varenicline With DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group carrying the DRD2 A1 allele'}, {'id': 'OG002', 'title': 'Bupropion w/o DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group not carrying the DRD2 A1 allele'}, {'id': 'OG003', 'title': 'Bupropion With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}, {'id': 'OG004', 'title': 'Placebo w/o DRD2 A1 Allele', 'description': 'Subjects in the Placebo group not carrying the DRD2 A1 allele'}, {'id': 'OG005', 'title': 'Placebo With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}], 'classes': [{'title': 'Emotional Reactivity (ORB) to Cigarette Stimuli', 'categories': [{'measurements': [{'value': '0.001', 'groupId': 'OG000', 'lowerLimit': '-0.002', 'upperLimit': '0.004'}, {'value': '-0.004', 'groupId': 'OG001', 'lowerLimit': '-0.008', 'upperLimit': '0'}, {'value': '0', 'groupId': 'OG002', 'lowerLimit': '-0.003', 'upperLimit': '0.003'}, {'value': '-0.003', 'groupId': 'OG003', 'lowerLimit': '-0.006', 'upperLimit': '0.001'}, {'value': '-0.001', 'groupId': 'OG004', 'lowerLimit': '-0.003', 'upperLimit': '0.001'}, {'value': '-0.004', 'groupId': 'OG005', 'lowerLimit': '-0.008', 'upperLimit': '0'}]}]}, {'title': 'Emotional Reactivity (ORB) to Negative Stimuli', 'categories': [{'measurements': [{'value': '0.002', 'groupId': 'OG000', 'lowerLimit': '-0.002', 'upperLimit': '0.005'}, {'value': '-0.005', 'groupId': 'OG001', 'lowerLimit': '-0.008', 'upperLimit': '-0.001'}, {'value': '0', 'groupId': 'OG002', 'lowerLimit': '-0.002', 'upperLimit': '0.002'}, {'value': '-0.004', 'groupId': 'OG003', 'lowerLimit': '-0.007', 'upperLimit': '0.001'}, {'value': '-0.001', 'groupId': 'OG004', 'lowerLimit': '-0.003', 'upperLimit': '0.001'}, {'value': '-0.004', 'groupId': 'OG005', 'lowerLimit': '-0.008', 'upperLimit': '0'}]}]}, {'title': 'Emotional Reactivity (ORB) to Positive Stimuli', 'categories': [{'measurements': [{'value': '0.001', 'groupId': 'OG000', 'lowerLimit': '-0.002', 'upperLimit': '0.005'}, {'value': '-0.005', 'groupId': 'OG001', 'lowerLimit': '-0.009', 'upperLimit': '-0.001'}, {'value': '0', 'groupId': 'OG002', 'lowerLimit': '-0.003', 'upperLimit': '0.002'}, {'value': '-0.003', 'groupId': 'OG003', 'lowerLimit': '-0.006', 'upperLimit': '0'}, {'value': '-0.001', 'groupId': 'OG004', 'lowerLimit': '-0.003', 'upperLimit': '0.001'}, {'value': '-0.004', 'groupId': 'OG005', 'lowerLimit': '-0.007', 'upperLimit': '0'}]}]}, {'title': 'Emotional Reactivity (ORB) to Neutral Stimuli', 'categories': [{'measurements': [{'value': '0.001', 'groupId': 'OG000', 'lowerLimit': '-0.002', 'upperLimit': '0.005'}, {'value': '-0.005', 'groupId': 'OG001', 'lowerLimit': '-0.009', 'upperLimit': '-0.001'}, {'value': '0.001', 'groupId': 'OG002', 'lowerLimit': '-0.002', 'upperLimit': '0.003'}, {'value': '-0.002', 'groupId': 'OG003', 'lowerLimit': '-0.005', 'upperLimit': '0.001'}, {'value': '-0.001', 'groupId': 'OG004', 'lowerLimit': '-0.003', 'upperLimit': '0.001'}, {'value': '-0.003', 'groupId': 'OG005', 'lowerLimit': '-0.007', 'upperLimit': '0.001'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 3 Month', 'description': 'Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.', 'unitOfMeasure': 'probability', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': '13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.'}, {'type': 'SECONDARY', 'title': 'Smoking Abstinence at 6 Months', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '90', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline', 'description': 'Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).\n\nVarenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)'}, {'id': 'OG001', 'title': 'Bupropion', 'description': 'Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).\n\nBupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Placebo by mouth for 12 weeks.\n\nPlacebo: Placebo by mouth for 12 weeks.'}], 'classes': [{'title': 'Emotional Reactivity (ORB) to Cigaretee Stimuli', 'categories': [{'measurements': [{'value': '0.007', 'groupId': 'OG000', 'lowerLimit': '-0.067', 'upperLimit': '0.082'}, {'value': '-0.002', 'groupId': 'OG001', 'lowerLimit': '-0.073', 'upperLimit': '0.069'}, {'value': '-0.006', 'groupId': 'OG002', 'lowerLimit': '-0.091', 'upperLimit': '0.079'}]}]}, {'title': 'Emotional Reactivity (ORB) to Negative Stimuli', 'categories': [{'measurements': [{'value': '0.008', 'groupId': 'OG000', 'lowerLimit': '-0.069', 'upperLimit': '0.085'}, {'value': '-0.003', 'groupId': 'OG001', 'lowerLimit': '-0.067', 'upperLimit': '0.062'}, {'value': '-0.005', 'groupId': 'OG002', 'lowerLimit': '-0.081', 'upperLimit': '0.071'}]}]}, {'title': 'Emotional Reactivity (ORB) to Positive Stimuli', 'categories': [{'measurements': [{'value': '0.01', 'groupId': 'OG000', 'lowerLimit': '-0.065', 'upperLimit': '0.086'}, {'value': '-0.003', 'groupId': 'OG001', 'lowerLimit': '-0.075', 'upperLimit': '0.068'}, {'value': '-0.005', 'groupId': 'OG002', 'lowerLimit': '-0.087', 'upperLimit': '0.078'}]}]}, {'title': 'Emotional Reactivity (ORB) to Neutral Stimuli', 'categories': [{'measurements': [{'value': '0.008', 'groupId': 'OG000', 'lowerLimit': '-0.071', 'upperLimit': '0.087'}, {'value': '-0.001', 'groupId': 'OG001', 'lowerLimit': '-0.078', 'upperLimit': '0.076'}, {'value': '-0.005', 'groupId': 'OG002', 'lowerLimit': '-0.052', 'upperLimit': '0.041'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Abstinence at 6 Months ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)', 'description': 'Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.', 'unitOfMeasure': 'probability', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Abstinence at 6 Months by DRD2 A1 Allele', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline w/o DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group not carrying the DRD2 A1 allele'}, {'id': 'OG001', 'title': 'Varenicline With DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group carrying the DRD2 A1 allele'}, {'id': 'OG002', 'title': 'Bupropion w/o DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group not carrying the DRD2 A1 allele'}, {'id': 'OG003', 'title': 'Bupropion With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}, {'id': 'OG004', 'title': 'Placebo w/o DRD2 A1 Allele', 'description': 'Subjects in the Placebo group not carrying the DRD2 A1 allele'}, {'id': 'OG005', 'title': 'Placebo With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}], 'classes': [{'title': 'Emotional Reactivity (ORB) to Cigarette Stimuli', 'categories': [{'measurements': [{'value': '0.003', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '0.005'}, {'value': '-0.001', 'groupId': 'OG001', 'lowerLimit': '-0.005', 'upperLimit': '0.003'}, {'value': '0.001', 'groupId': 'OG002', 'lowerLimit': '-0.002', 'upperLimit': '0.003'}, {'value': '-0.001', 'groupId': 'OG003', 'lowerLimit': '-0.004', 'upperLimit': '0.002'}, {'value': '0', 'groupId': 'OG004', 'lowerLimit': '-0.002', 'upperLimit': '0.001'}, {'value': '-0.005', 'groupId': 'OG005', 'lowerLimit': '-0.01', 'upperLimit': '0'}]}]}, {'title': 'Emotional Reactivity (ORB) to Negative Stimuli', 'categories': [{'measurements': [{'value': '0.003', 'groupId': 'OG000', 'lowerLimit': '0.001', 'upperLimit': '0.005'}, {'value': '-0.001', 'groupId': 'OG001', 'lowerLimit': '-0.005', 'upperLimit': '0.003'}, {'value': '0.001', 'groupId': 'OG002', 'lowerLimit': '-0.001', 'upperLimit': '0.003'}, {'value': '-0.002', 'groupId': 'OG003', 'lowerLimit': '-0.005', 'upperLimit': '0.001'}, {'value': '0', 'groupId': 'OG004', 'lowerLimit': '-0.002', 'upperLimit': '0.001'}, {'value': '-0.004', 'groupId': 'OG005', 'lowerLimit': '-0.008', 'upperLimit': '0'}]}]}, {'title': 'Emotional Reactivity (ORB) to Positive Stimuli', 'categories': [{'measurements': [{'value': '0.003', 'groupId': 'OG000', 'lowerLimit': '0.001', 'upperLimit': '0.006'}, {'value': '0', 'groupId': 'OG001', 'lowerLimit': '-0.005', 'upperLimit': '0.004'}, {'value': '0', 'groupId': 'OG002', 'lowerLimit': '-0.002', 'upperLimit': '0.003'}, {'value': '-0.001', 'groupId': 'OG003', 'lowerLimit': '-0.004', 'upperLimit': '0.002'}, {'value': '0', 'groupId': 'OG004', 'lowerLimit': '-0.002', 'upperLimit': '0.002'}, {'value': '-0.004', 'groupId': 'OG005', 'lowerLimit': '-0.008', 'upperLimit': '0'}]}]}, {'title': 'Emotional Reactivity (ORB) to Neutral Stimuli', 'categories': [{'measurements': [{'value': '0.003', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '0.005'}, {'value': '-0.001', 'groupId': 'OG001', 'lowerLimit': '-0.005', 'upperLimit': '0.003'}, {'value': '0.001', 'groupId': 'OG002', 'lowerLimit': '-0.002', 'upperLimit': '0.004'}, {'value': '-0.001', 'groupId': 'OG003', 'lowerLimit': '-0.004', 'upperLimit': '0.002'}, {'value': '0', 'groupId': 'OG004', 'lowerLimit': '-0.002', 'upperLimit': '0.001'}, {'value': '-0.004', 'groupId': 'OG005', 'lowerLimit': '-0.009', 'upperLimit': '0'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 6 Month ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)', 'description': 'Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.', 'unitOfMeasure': 'probability', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': '13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.'}, {'type': 'SECONDARY', 'title': 'Symptoms of Nicotine Withdrawal Using the Wisconsin Smoking Withdrawal Scale (WSWS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline w/o DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group not carrying the DRD2 A1 allele'}, {'id': 'OG001', 'title': 'Varenicline With DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group carrying the DRD2 A1 allele'}, {'id': 'OG002', 'title': 'Bupropion w/o DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group not carrying the DRD2 A1 allele'}, {'id': 'OG003', 'title': 'Bupropion With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}, {'id': 'OG004', 'title': 'Placebo w/o DRD2 A1 Allele', 'description': 'Subjects in the Placebo group not carrying the DRD2 A1 allele'}, {'id': 'OG005', 'title': 'Placebo With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}], 'classes': [{'title': 'Anger', 'categories': [{'measurements': [{'value': '4.394', 'groupId': 'OG000', 'lowerLimit': '3.629', 'upperLimit': '5.159'}, {'value': '4.222', 'groupId': 'OG001', 'lowerLimit': '3.152', 'upperLimit': '5.291'}, {'value': '4.28', 'groupId': 'OG002', 'lowerLimit': '3.402', 'upperLimit': '5.157'}, {'value': '4.41', 'groupId': 'OG003', 'lowerLimit': '3.59', 'upperLimit': '5.23'}, {'value': '5.584', 'groupId': 'OG004', 'lowerLimit': '4.744', 'upperLimit': '6.424'}, {'value': '5.752', 'groupId': 'OG005', 'lowerLimit': '4.884', 'upperLimit': '6.621'}]}]}, {'title': 'Anxiety', 'categories': [{'measurements': [{'value': '6.218', 'groupId': 'OG000', 'lowerLimit': '5.384', 'upperLimit': '7.052'}, {'value': '5.873', 'groupId': 'OG001', 'lowerLimit': '4.707', 'upperLimit': '7.038'}, {'value': '6.587', 'groupId': 'OG002', 'lowerLimit': '5.63', 'upperLimit': '7.543'}, {'value': '6.587', 'groupId': 'OG003', 'lowerLimit': '5.63', 'upperLimit': '7.543'}, {'value': '7.785', 'groupId': 'OG004', 'lowerLimit': '6.87', 'upperLimit': '8.7'}, {'value': '7.915', 'groupId': 'OG005', 'lowerLimit': '6.968', 'upperLimit': '8.862'}]}]}, {'title': 'Concentration', 'categories': [{'measurements': [{'value': '3.743', 'groupId': 'OG000', 'lowerLimit': '3.117', 'upperLimit': '4.369'}, {'value': '3.407', 'groupId': 'OG001', 'lowerLimit': '2.531', 'upperLimit': '4.282'}, {'value': '4.238', 'groupId': 'OG002', 'lowerLimit': '3.521', 'upperLimit': '4.956'}, {'value': '3.935', 'groupId': 'OG003', 'lowerLimit': '3.265', 'upperLimit': '4.605'}, {'value': '4.764', 'groupId': 'OG004', 'lowerLimit': '4.077', 'upperLimit': '5.451'}, {'value': '4.951', 'groupId': 'OG005', 'lowerLimit': '4.242', 'upperLimit': '5.66'}]}]}, {'title': 'Craving', 'categories': [{'measurements': [{'value': '6.646', 'groupId': 'OG000', 'lowerLimit': '5.591', 'upperLimit': '7.701'}, {'value': '6.252', 'groupId': 'OG001', 'lowerLimit': '4.777', 'upperLimit': '7.726'}, {'value': '6.814', 'groupId': 'OG002', 'lowerLimit': '5.605', 'upperLimit': '8.024'}, {'value': '6.78', 'groupId': 'OG003', 'lowerLimit': '5.651', 'upperLimit': '7.91'}, {'value': '9.024', 'groupId': 'OG004', 'lowerLimit': '7.866', 'upperLimit': '10.181'}, {'value': '8.696', 'groupId': 'OG005', 'lowerLimit': '7.499', 'upperLimit': '9.893'}]}]}, {'title': 'Hunger', 'categories': [{'measurements': [{'value': '11.016', 'groupId': 'OG000', 'lowerLimit': '10.09', 'upperLimit': '11.942'}, {'value': '10.707', 'groupId': 'OG001', 'lowerLimit': '9.413', 'upperLimit': '12.001'}, {'value': '9.79', 'groupId': 'OG002', 'lowerLimit': '8.729', 'upperLimit': '10.852'}, {'value': '11.082', 'groupId': 'OG003', 'lowerLimit': '10.09', 'upperLimit': '12.074'}, {'value': '11.207', 'groupId': 'OG004', 'lowerLimit': '10.19', 'upperLimit': '12.223'}, {'value': '11.044', 'groupId': 'OG005', 'lowerLimit': '9.994', 'upperLimit': '12.095'}]}]}, {'title': 'Sadness', 'categories': [{'measurements': [{'value': '4.246', 'groupId': 'OG000', 'lowerLimit': '3.535', 'upperLimit': '4.958'}, {'value': '3.738', 'groupId': 'OG001', 'lowerLimit': '2.744', 'upperLimit': '4.732'}, {'value': '4.005', 'groupId': 'OG002', 'lowerLimit': '3.189', 'upperLimit': '4.82'}, {'value': '4.338', 'groupId': 'OG003', 'lowerLimit': '3.577', 'upperLimit': '5.1'}, {'value': '5.293', 'groupId': 'OG004', 'lowerLimit': '4.513', 'upperLimit': '6.074'}, {'value': '5.865', 'groupId': 'OG005', 'lowerLimit': '5.057', 'upperLimit': '6.673'}]}]}, {'title': 'Sleep', 'categories': [{'measurements': [{'value': '7.721', 'groupId': 'OG000', 'lowerLimit': '6.494', 'upperLimit': '8.948'}, {'value': '8.153', 'groupId': 'OG001', 'lowerLimit': '6.438', 'upperLimit': '9.868'}, {'value': '9.672', 'groupId': 'OG002', 'lowerLimit': '8.265', 'upperLimit': '11.079'}, {'value': '9.528', 'groupId': 'OG003', 'lowerLimit': '8.214', 'upperLimit': '10.843'}, {'value': '9.078', 'groupId': 'OG004', 'lowerLimit': '7.731', 'upperLimit': '10.424'}, {'value': '8.629', 'groupId': 'OG005', 'lowerLimit': '7.236', 'upperLimit': '10.023'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 8 months', 'description': 'Symptoms of nicotine withdrawal measured using Wisconsin Smoking Withdrawal Scale (WSWS). The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). A single value was estimated by averaging within the specific time interval. Higher values represent worse outcome. The average value was estimated from Baseline to 8 months', 'unitOfMeasure': 'score on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': '13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.'}, {'type': 'SECONDARY', 'title': 'Symptoms of Nicotine Withdrawal and Negative Affect Using Positive and Negative Affect Scale (PANAS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline w/o DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group not carrying the DRD2 A1 allele'}, {'id': 'OG001', 'title': 'Varenicline With DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group carrying the DRD2 A1 allele'}, {'id': 'OG002', 'title': 'Bupropion w/o DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group not carrying the DRD2 A1 allele'}, {'id': 'OG003', 'title': 'Bupropion With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}, {'id': 'OG004', 'title': 'Placebo w/o DRD2 A1 Allele', 'description': 'Subjects in the Placebo group not carrying the DRD2 A1 allele'}, {'id': 'OG005', 'title': 'Placebo With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}], 'classes': [{'title': 'Positive Affect', 'categories': [{'measurements': [{'value': '35.507', 'groupId': 'OG000', 'lowerLimit': '33.494', 'upperLimit': '37.521'}, {'value': '37.315', 'groupId': 'OG001', 'lowerLimit': '34.5', 'upperLimit': '40.13'}, {'value': '36.429', 'groupId': 'OG002', 'lowerLimit': '34.122', 'upperLimit': '38.735'}, {'value': '35.281', 'groupId': 'OG003', 'lowerLimit': '33.125', 'upperLimit': '37.437'}, {'value': '33.672', 'groupId': 'OG004', 'lowerLimit': '31.463', 'upperLimit': '35.882'}, {'value': '33.984', 'groupId': 'OG005', 'lowerLimit': '31.709', 'upperLimit': '36.259'}]}]}, {'title': 'Negative Affect', 'categories': [{'measurements': [{'value': '15.93', 'groupId': 'OG000', 'lowerLimit': '14.404', 'upperLimit': '17.455'}, {'value': '14.98', 'groupId': 'OG001', 'lowerLimit': '12.849', 'upperLimit': '17.112'}, {'value': '15.782', 'groupId': 'OG002', 'lowerLimit': '14.032', 'upperLimit': '17.532'}, {'value': '16.385', 'groupId': 'OG003', 'lowerLimit': '14.751', 'upperLimit': '18.02'}, {'value': '18.017', 'groupId': 'OG004', 'lowerLimit': '16.343', 'upperLimit': '19.691'}, {'value': '18.902', 'groupId': 'OG005', 'lowerLimit': '17.166', 'upperLimit': '20.638'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 8 months', 'description': 'Symptoms of nicotine withdrawal and negative affect were measured using the Positive and Negative Affect Scale (PANAS). The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The average value was estimated from Baseline to 8 months', 'unitOfMeasure': 'score on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': '13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.'}, {'type': 'SECONDARY', 'title': 'Symptoms of Depression Using the Center for Epidemiologic Studies Depression Scale (CES-D)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline w/o DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group not carrying the DRD2 A1 allele'}, {'id': 'OG001', 'title': 'Varenicline With DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group carrying the DRD2 A1 allele'}, {'id': 'OG002', 'title': 'Bupropion w/o DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group not carrying the DRD2 A1 allele'}, {'id': 'OG003', 'title': 'Bupropion With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}, {'id': 'OG004', 'title': 'Placebo w/o DRD2 A1 Allele', 'description': 'Subjects in the Placebo group not carrying the DRD2 A1 allele'}, {'id': 'OG005', 'title': 'Placebo With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}], 'classes': [{'categories': [{'measurements': [{'value': '8.084', 'groupId': 'OG000', 'lowerLimit': '6.19', 'upperLimit': '9.978'}, {'value': '6.847', 'groupId': 'OG001', 'lowerLimit': '4.2', 'upperLimit': '9.494'}, {'value': '7.588', 'groupId': 'OG002', 'lowerLimit': '5.416', 'upperLimit': '9.76'}, {'value': '8.362', 'groupId': 'OG003', 'lowerLimit': '6.333', 'upperLimit': '10.39'}, {'value': '8.65', 'groupId': 'OG004', 'lowerLimit': '6.572', 'upperLimit': '10.729'}, {'value': '10.799', 'groupId': 'OG005', 'lowerLimit': '8.647', 'upperLimit': '12.951'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 8 months', 'description': 'Symptoms of nicotine withdrawal measured using Center for Epidemiologic Studies Depression Scale (CES-D). Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The average value was estimated from Baseline to 8 months', 'unitOfMeasure': 'score on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': '13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.'}, {'type': 'SECONDARY', 'title': 'Measures of Smoking Satisfaction and Psychological Reward Using the Modified Cigarette Evaluation Questionnaire (mCEQ) Subscales', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline w/o DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group not carrying the DRD2 A1 allele'}, {'id': 'OG001', 'title': 'Varenicline With DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group carrying the DRD2 A1 allele'}, {'id': 'OG002', 'title': 'Bupropion w/o DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group not carrying the DRD2 A1 allele'}, {'id': 'OG003', 'title': 'Bupropion With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}, {'id': 'OG004', 'title': 'Placebo w/o DRD2 A1 Allele', 'description': 'Subjects in the Placebo group not carrying the DRD2 A1 allele'}, {'id': 'OG005', 'title': 'Placebo With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}], 'classes': [{'title': 'Smoking Satisfaction', 'categories': [{'measurements': [{'value': '2.895', 'groupId': 'OG000', 'lowerLimit': '1.912', 'upperLimit': '3.879'}, {'value': '2.591', 'groupId': 'OG001', 'lowerLimit': '1.253', 'upperLimit': '3.93'}, {'value': '4.064', 'groupId': 'OG002', 'lowerLimit': '2.94', 'upperLimit': '5.187'}, {'value': '3.369', 'groupId': 'OG003', 'lowerLimit': '2.135', 'upperLimit': '4.603'}, {'value': '3.025', 'groupId': 'OG004', 'lowerLimit': '2.087', 'upperLimit': '3.963'}, {'value': '3.515', 'groupId': 'OG005', 'lowerLimit': '2.368', 'upperLimit': '4.662'}]}]}, {'title': 'Psychological Reward', 'categories': [{'measurements': [{'value': '2.819', 'groupId': 'OG000', 'lowerLimit': '2.109', 'upperLimit': '3.528'}, {'value': '2.155', 'groupId': 'OG001', 'lowerLimit': '1.181', 'upperLimit': '3.13'}, {'value': '2.519', 'groupId': 'OG002', 'lowerLimit': '1.693', 'upperLimit': '3.346'}, {'value': '2.723', 'groupId': 'OG003', 'lowerLimit': '1.812', 'upperLimit': '3.634'}, {'value': '3.575', 'groupId': 'OG004', 'lowerLimit': '2.861', 'upperLimit': '4.289'}, {'value': '3.246', 'groupId': 'OG005', 'lowerLimit': '2.399', 'upperLimit': '4.093'}]}]}, {'title': 'Aversion', 'categories': [{'measurements': [{'value': '1.612', 'groupId': 'OG000', 'lowerLimit': '1.357', 'upperLimit': '1.867'}, {'value': '1.694', 'groupId': 'OG001', 'lowerLimit': '1.342', 'upperLimit': '2.045'}, {'value': '1.988', 'groupId': 'OG002', 'lowerLimit': '1.69', 'upperLimit': '2.286'}, {'value': '1.79', 'groupId': 'OG003', 'lowerLimit': '1.461', 'upperLimit': '2.119'}, {'value': '1.808', 'groupId': 'OG004', 'lowerLimit': '1.549', 'upperLimit': '2.067'}, {'value': '1.69', 'groupId': 'OG005', 'lowerLimit': '1.384', 'upperLimit': '1.996'}]}]}, {'title': 'Enjoyment of Respiratory Tract Sensation', 'categories': [{'measurements': [{'value': '1.912', 'groupId': 'OG000', 'lowerLimit': '0.146', 'upperLimit': '3.678'}, {'value': '1.703', 'groupId': 'OG001', 'lowerLimit': '-0.692', 'upperLimit': '4.099'}, {'value': '4.096', 'groupId': 'OG002', 'lowerLimit': '2.094', 'upperLimit': '6.099'}, {'value': '1.955', 'groupId': 'OG003', 'lowerLimit': '-0.243', 'upperLimit': '4.153'}, {'value': '3.711', 'groupId': 'OG004', 'lowerLimit': '2.048', 'upperLimit': '5.375'}, {'value': '2.783', 'groupId': 'OG005', 'lowerLimit': '0.741', 'upperLimit': '4.825'}]}]}, {'title': 'Craving Reduction', 'categories': [{'measurements': [{'value': '4.531', 'groupId': 'OG000', 'lowerLimit': '3.232', 'upperLimit': '5.831'}, {'value': '3.952', 'groupId': 'OG001', 'lowerLimit': '2.2', 'upperLimit': '5.705'}, {'value': '4.564', 'groupId': 'OG002', 'lowerLimit': '3.083', 'upperLimit': '6.044'}, {'value': '6.628', 'groupId': 'OG003', 'lowerLimit': '5.017', 'upperLimit': '8.238'}, {'value': '4.486', 'groupId': 'OG004', 'lowerLimit': '3.269', 'upperLimit': '5.702'}, {'value': '4.673', 'groupId': 'OG005', 'lowerLimit': '3.176', 'upperLimit': '6.17'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 8 months', 'description': 'Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items.', 'unitOfMeasure': 'score on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': '13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.'}, {'type': 'SECONDARY', 'title': 'Skin Conductance Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline w/o DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group not carrying the DRD2 A1 allele'}, {'id': 'OG001', 'title': 'Varenicline With DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group carrying the DRD2 A1 allele'}, {'id': 'OG002', 'title': 'Bupropion w/o DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group not carrying the DRD2 A1 allele'}, {'id': 'OG003', 'title': 'Bupropion With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}, {'id': 'OG004', 'title': 'Placebo w/o DRD2 A1 Allele', 'description': 'Subjects in the Placebo group not carrying the DRD2 A1 allele'}, {'id': 'OG005', 'title': 'Placebo With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}], 'classes': [{'title': 'Skin conductance to Cigarette Stimuli', 'categories': [{'measurements': [{'value': '2.301', 'groupId': 'OG000', 'lowerLimit': '1.619', 'upperLimit': '2.982'}, {'value': '2.016', 'groupId': 'OG001', 'lowerLimit': '1.132', 'upperLimit': '2.901'}, {'value': '2.275', 'groupId': 'OG002', 'lowerLimit': '1.512', 'upperLimit': '3.037'}, {'value': '1.797', 'groupId': 'OG003', 'lowerLimit': '1.082', 'upperLimit': '2.511'}, {'value': '2.272', 'groupId': 'OG004', 'lowerLimit': '1.54', 'upperLimit': '3.005'}, {'value': '2.443', 'groupId': 'OG005', 'lowerLimit': '1.703', 'upperLimit': '3.183'}]}]}, {'title': 'Skin conductance to Negative Stimuli', 'categories': [{'measurements': [{'value': '2.295', 'groupId': 'OG000', 'lowerLimit': '1.613', 'upperLimit': '2.976'}, {'value': '1.969', 'groupId': 'OG001', 'lowerLimit': '1.084', 'upperLimit': '2.855'}, {'value': '2.31', 'groupId': 'OG002', 'lowerLimit': '1.547', 'upperLimit': '3.072'}, {'value': '1.695', 'groupId': 'OG003', 'lowerLimit': '0.999', 'upperLimit': '2.391'}, {'value': '2.355', 'groupId': 'OG004', 'lowerLimit': '1.611', 'upperLimit': '3.099'}, {'value': '2.485', 'groupId': 'OG005', 'lowerLimit': '1.756', 'upperLimit': '3.215'}]}]}, {'title': 'Skin conductance to Positive Stimuli', 'categories': [{'measurements': [{'value': '2.256', 'groupId': 'OG000', 'lowerLimit': '1.58', 'upperLimit': '2.931'}, {'value': '1.984', 'groupId': 'OG001', 'lowerLimit': '1.106', 'upperLimit': '2.862'}, {'value': '2.299', 'groupId': 'OG002', 'lowerLimit': '1.542', 'upperLimit': '3.055'}, {'value': '1.7', 'groupId': 'OG003', 'lowerLimit': '1.01', 'upperLimit': '2.39'}, {'value': '2.296', 'groupId': 'OG004', 'lowerLimit': '1.569', 'upperLimit': '3.023'}, {'value': '2.565', 'groupId': 'OG005', 'lowerLimit': '1.831', 'upperLimit': '3.299'}]}]}, {'title': 'Skin conductance to Neutral Stimuli', 'categories': [{'measurements': [{'value': '2.261', 'groupId': 'OG000', 'lowerLimit': '1.578', 'upperLimit': '2.944'}, {'value': '2.017', 'groupId': 'OG001', 'lowerLimit': '1.13', 'upperLimit': '2.904'}, {'value': '2.369', 'groupId': 'OG002', 'lowerLimit': '1.602', 'upperLimit': '3.136'}, {'value': '1.699', 'groupId': 'OG003', 'lowerLimit': '1.002', 'upperLimit': '2.397'}, {'value': '2.362', 'groupId': 'OG004', 'lowerLimit': '1.616', 'upperLimit': '3.107'}, {'value': '2.559', 'groupId': 'OG005', 'lowerLimit': '1.82', 'upperLimit': '3.299'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 1 month', 'description': 'Skin conductance response (SCR) amplitude measured by placing an electrodermal response transducer on the fore and ring fingers of the participants non-dominant hand, and heart rate (HR) was collected by placing a photoelectric pulse plethysmogram transducer on the middle finger of the participants non-dominant hand, during the presentation of emotionally valent stimuli (positive, negative, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.', 'unitOfMeasure': 'Microsiemens', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': '13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.'}, {'type': 'SECONDARY', 'title': 'Heart Rate Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Varenicline w/o DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group not carrying the DRD2 A1 allele'}, {'id': 'OG001', 'title': 'Varenicline With DRD2 A1 Allele', 'description': 'Subjects in the Varenicline group carrying the DRD2 A1 allele'}, {'id': 'OG002', 'title': 'Bupropion w/o DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group not carrying the DRD2 A1 allele'}, {'id': 'OG003', 'title': 'Bupropion With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}, {'id': 'OG004', 'title': 'Placebo w/o DRD2 A1 Allele', 'description': 'Subjects in the Placebo group not carrying the DRD2 A1 allele'}, {'id': 'OG005', 'title': 'Placebo With DRD2 A1 Allele', 'description': 'Subjects in the Bupropion group carrying the DRD2 A1 allele'}], 'classes': [{'title': 'Heart Rate response to Cigarette Stimuli', 'categories': [{'measurements': [{'value': '69.731', 'groupId': 'OG000', 'lowerLimit': '66.962', 'upperLimit': '72.5'}, {'value': '68.652', 'groupId': 'OG001', 'lowerLimit': '65.068', 'upperLimit': '72.236'}, {'value': '71.427', 'groupId': 'OG002', 'lowerLimit': '68.331', 'upperLimit': '74.524'}, {'value': '69.836', 'groupId': 'OG003', 'lowerLimit': '66.974', 'upperLimit': '72.699'}, {'value': '65.966', 'groupId': 'OG004', 'lowerLimit': '62.987', 'upperLimit': '68.944'}, {'value': '65.276', 'groupId': 'OG005', 'lowerLimit': '62.266', 'upperLimit': '68.286'}]}]}, {'title': 'Heart Rate response to Negative Stimuli', 'categories': [{'measurements': [{'value': '69.562', 'groupId': 'OG000', 'lowerLimit': '66.722', 'upperLimit': '72.402'}, {'value': '68.078', 'groupId': 'OG001', 'lowerLimit': '64.403', 'upperLimit': '71.753'}, {'value': '71.077', 'groupId': 'OG002', 'lowerLimit': '67.904', 'upperLimit': '74.25'}, {'value': '69.595', 'groupId': 'OG003', 'lowerLimit': '66.699', 'upperLimit': '72.492'}, {'value': '65.768', 'groupId': 'OG004', 'lowerLimit': '62.713', 'upperLimit': '68.823'}, {'value': '65.569', 'groupId': 'OG005', 'lowerLimit': '62.523', 'upperLimit': '68.615'}]}]}, {'title': 'Heart Rate response to Positive Stimuli', 'categories': [{'measurements': [{'value': '69.151', 'groupId': 'OG000', 'lowerLimit': '66.351', 'upperLimit': '71.95'}, {'value': '68.711', 'groupId': 'OG001', 'lowerLimit': '65.087', 'upperLimit': '72.334'}, {'value': '71.518', 'groupId': 'OG002', 'lowerLimit': '68.386', 'upperLimit': '74.65'}, {'value': '70.404', 'groupId': 'OG003', 'lowerLimit': '67.546', 'upperLimit': '73.262'}, {'value': '65.787', 'groupId': 'OG004', 'lowerLimit': '62.776', 'upperLimit': '68.799'}, {'value': '65.927', 'groupId': 'OG005', 'lowerLimit': '62.929', 'upperLimit': '68.926'}]}]}, {'title': 'Heart Rate response to Neutral Stimuli', 'categories': [{'measurements': [{'value': '69.621', 'groupId': 'OG000', 'lowerLimit': '66.798', 'upperLimit': '72.444'}, {'value': '68.969', 'groupId': 'OG001', 'lowerLimit': '65.315', 'upperLimit': '72.624'}, {'value': '71.706', 'groupId': 'OG002', 'lowerLimit': '68.546', 'upperLimit': '74.865'}, {'value': '70.234', 'groupId': 'OG003', 'lowerLimit': '67.351', 'upperLimit': '73.117'}, {'value': '65.237', 'groupId': 'OG004', 'lowerLimit': '62.2', 'upperLimit': '68.273'}, {'value': '66.04', 'groupId': 'OG005', 'lowerLimit': '62.981', 'upperLimit': '69.098'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to 1 month', 'description': 'Heart Rate Response. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.', 'unitOfMeasure': 'beats per minute', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Varenicline', 'description': 'Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).\n\nVarenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)'}, {'id': 'FG001', 'title': 'Bupropion', 'description': 'Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).\n\nBupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)'}, {'id': 'FG002', 'title': 'Placebo', 'description': 'Placebo by mouth for 12 weeks.\n\nPlacebo: Placebo by mouth for 12 weeks.'}], 'periods': [{'title': 'Randomization to Month 3', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '75'}, {'groupId': 'FG001', 'numSubjects': '89'}, {'groupId': 'FG002', 'numSubjects': '90'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '60'}, {'groupId': 'FG001', 'numSubjects': '75'}, {'groupId': 'FG002', 'numSubjects': '70'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '14'}, {'groupId': 'FG002', 'numSubjects': '20'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '14'}, {'groupId': 'FG002', 'numSubjects': '20'}]}]}, {'title': 'From 3 Months to 6 Months', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '60'}, {'groupId': 'FG001', 'numSubjects': '75'}, {'groupId': 'FG002', 'numSubjects': '70'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '54'}, {'groupId': 'FG001', 'numSubjects': '65'}, {'groupId': 'FG002', 'numSubjects': '61'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '10'}, {'groupId': 'FG002', 'numSubjects': '9'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '10'}, {'groupId': 'FG002', 'numSubjects': '9'}]}]}], 'recruitmentDetails': 'A total of 254 subjects were randomized (varenicline: 75; bupropion: 89; placebo: 90 between December 2005 through October 2010. All subjects were residing in the Greater Houston Area and the study was completed at UT MD Anderson Cancer Center.', 'preAssignmentDetails': '646 participants signed consent, 392 were screen failures'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'BG000'}, {'value': '89', 'groupId': 'BG001'}, {'value': '90', 'groupId': 'BG002'}, {'value': '254', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'Varenicline', 'description': 'Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).\n\nVarenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)'}, {'id': 'BG001', 'title': 'Bupropion', 'description': 'Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).\n\nBupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)'}, {'id': 'BG002', 'title': 'Placebo', 'description': 'Placebo by mouth for 12 weeks.\n\nPlacebo: Placebo by mouth for 12 weeks.'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '43.5', 'spread': '10.8', 'groupId': 'BG000'}, {'value': '44.5', 'spread': '9.3', 'groupId': 'BG001'}, {'value': '45.7', 'spread': '10.9', 'groupId': 'BG002'}, {'value': '44.6', 'spread': '10.35', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '30', 'groupId': 'BG000'}, {'value': '34', 'groupId': 'BG001'}, {'value': '34', 'groupId': 'BG002'}, {'value': '98', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '45', 'groupId': 'BG000'}, {'value': '55', 'groupId': 'BG001'}, {'value': '56', 'groupId': 'BG002'}, {'value': '156', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '11', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '24', 'groupId': 'BG003'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '63', 'groupId': 'BG000'}, {'value': '82', 'groupId': 'BG001'}, {'value': '80', 'groupId': 'BG002'}, {'value': '225', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}]}, {'title': 'Asian', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}, {'title': 'Black or African American', 'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}, {'value': '63', 'groupId': 'BG003'}]}, {'title': 'White', 'measurements': [{'value': '39', 'groupId': 'BG000'}, {'value': '57', 'groupId': 'BG001'}, {'value': '60', 'groupId': 'BG002'}, {'value': '156', 'groupId': 'BG003'}]}, {'title': 'More than one race', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '20', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '7', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '75', 'groupId': 'BG000'}, {'value': '89', 'groupId': 'BG001'}, {'value': '90', 'groupId': 'BG002'}, {'value': '254', 'groupId': 'BG003'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Demographic and individual-level characteristics Wisconsin Smoking Withdrawal Scale (WSWS)', 'classes': [{'title': 'WSWS Anger Subscale', 'categories': [{'measurements': [{'value': '3.8', 'spread': '2.6', 'groupId': 'BG000'}, {'value': '4.2', 'spread': '2.7', 'groupId': 'BG001'}, {'value': '4.2', 'spread': '7.9', 'groupId': 'BG002'}, {'value': '4.1', 'spread': '2.6', 'groupId': 'BG003'}]}]}, {'title': 'WSWS Anxiety Subscale', 'categories': [{'measurements': [{'value': '7.3', 'spread': '2.7', 'groupId': 'BG000'}, {'value': '7.3', 'spread': '3.2', 'groupId': 'BG001'}, {'value': '7.9', 'spread': '3.3', 'groupId': 'BG002'}, {'value': '7.5', 'spread': '3.1', 'groupId': 'BG003'}]}]}, {'title': 'WSWS Concentration Subscale', 'categories': [{'measurements': [{'value': '3.7', 'spread': '1.9', 'groupId': 'BG000'}, {'value': '4', 'spread': '2.2', 'groupId': 'BG001'}, {'value': '3.9', 'spread': '2.2', 'groupId': 'BG002'}, {'value': '3.9', 'spread': '2.1', 'groupId': 'BG003'}]}]}, {'title': 'WSWS Craving Subscale', 'categories': [{'measurements': [{'value': '8.7', 'spread': '3.1', 'groupId': 'BG000'}, {'value': '9.4', 'spread': '2.8', 'groupId': 'BG001'}, {'value': '9.1', 'spread': '2.6', 'groupId': 'BG002'}, {'value': '9.1', 'spread': '2.8', 'groupId': 'BG003'}]}]}, {'title': 'WSWS Hunger Subscale', 'categories': [{'measurements': [{'value': '9.6', 'spread': '3.7', 'groupId': 'BG000'}, {'value': '9.8', 'spread': '3.3', 'groupId': 'BG001'}, {'value': '11.2', 'spread': '3.7', 'groupId': 'BG002'}, {'value': '10.2', 'spread': '3.6', 'groupId': 'BG003'}]}]}, {'title': 'WSWS Sadness Subscale', 'categories': [{'measurements': [{'value': '4.6', 'spread': '2.5', 'groupId': 'BG000'}, {'value': '4.2', 'spread': '2.4', 'groupId': 'BG001'}, {'value': '4.7', 'spread': '2.5', 'groupId': 'BG002'}, {'value': '4.5', 'spread': '2.8', 'groupId': 'BG003'}]}]}, {'title': 'WSWS Sleep Subscale', 'categories': [{'measurements': [{'value': '7.7', 'spread': '4.3', 'groupId': 'BG000'}, {'value': '9.3', 'spread': '4.5', 'groupId': 'BG001'}, {'value': '8.6', 'spread': '4.4', 'groupId': 'BG002'}, {'value': '8.6', 'spread': '4.5', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'description': 'The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). Higher values, of all scales, represent worse outcomes', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Demographic and individual-level characteristics -Positive and Negative Affect Scales (PANAS)', 'classes': [{'title': 'PANAS Positive Affect', 'categories': [{'measurements': [{'value': '35.8', 'spread': '7.1', 'groupId': 'BG000'}, {'value': '36.1', 'spread': '5.7', 'groupId': 'BG001'}, {'value': '35.8', 'spread': '6.2', 'groupId': 'BG002'}, {'value': '35.9', 'spread': '6.3', 'groupId': 'BG003'}]}]}, {'title': 'PANAS Negative Affect', 'categories': [{'measurements': [{'value': '14.8', 'spread': '5.1', 'groupId': 'BG000'}, {'value': '15.6', 'spread': '6.9', 'groupId': 'BG001'}, {'value': '16.4', 'spread': '5.9', 'groupId': 'BG002'}, {'value': '15.6', 'spread': '5.3', 'groupId': 'BG003'}]}]}], 'paramType': 'MEDIAN', 'description': 'The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Demographic and individual-level characteristics - (CESD)', 'classes': [{'categories': [{'measurements': [{'value': '6.7', 'spread': '6.1', 'groupId': 'BG000'}, {'value': '6.9', 'spread': '6.1', 'groupId': 'BG001'}, {'value': '8.1', 'spread': '7.1', 'groupId': 'BG002'}, {'value': '7.3', 'spread': '6.5', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'description': 'Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Demographic and individual-level characteristics -Modified Cigarette Evaluation Questionnaire (mCEQ)', 'classes': [{'title': 'mCEQ Smoking Satisfaction', 'categories': [{'measurements': [{'value': '4.3', 'spread': '1.1', 'groupId': 'BG000'}, {'value': '3.9', 'spread': '1.2', 'groupId': 'BG001'}, {'value': '4.2', 'spread': '1.2', 'groupId': 'BG002'}, {'value': '4.2', 'spread': '1.2', 'groupId': 'BG003'}]}]}, {'title': 'mCEQ Psychological Reward', 'categories': [{'measurements': [{'value': '4.1', 'spread': '4.9', 'groupId': 'BG000'}, {'value': '3.7', 'spread': '1.1', 'groupId': 'BG001'}, {'value': '3.6', 'spread': '1.3', 'groupId': 'BG002'}, {'value': '3.8', 'spread': '3.1', 'groupId': 'BG003'}]}]}, {'title': 'mCEQ Aversion', 'categories': [{'measurements': [{'value': '1.6', 'spread': '0.8', 'groupId': 'BG000'}, {'value': '1.6', 'spread': '0.7', 'groupId': 'BG001'}, {'value': '1.5', 'spread': '0.8', 'groupId': 'BG002'}, {'value': '1.5', 'spread': '0.8', 'groupId': 'BG003'}]}]}, {'title': 'mCEQ Enjoyment of Respiratory Tract Sensation', 'categories': [{'measurements': [{'value': '2.9', 'spread': '1.5', 'groupId': 'BG000'}, {'value': '2.9', 'spread': '1.4', 'groupId': 'BG001'}, {'value': '2.9', 'spread': '1.4', 'groupId': 'BG002'}, {'value': '2.9', 'spread': '1.5', 'groupId': 'BG003'}]}]}, {'title': 'mCEQ Craving Reduction', 'categories': [{'measurements': [{'value': '5.1', 'spread': '1.5', 'groupId': 'BG000'}, {'value': '5.1', 'spread': '1.4', 'groupId': 'BG001'}, {'value': '4.9', 'spread': '1.6', 'groupId': 'BG002'}, {'value': '5', 'spread': '1.5', 'groupId': 'BG003'}]}]}], 'paramType': 'MEDIAN', 'description': 'Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items.', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'STANDARD_DEVIATION'}], 'populationDescription': 'The analysis dataset is comprised of all treated participants, i.e. Intention to Treat.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2004-02-24', 'size': 2646004, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2020-12-17T15:26', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2', 'PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 646}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2005-12-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-04', 'completionDateStruct': {'date': '2019-12-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-04-07', 'studyFirstSubmitDate': '2007-07-25', 'resultsFirstSubmitDate': '2020-12-18', 'studyFirstSubmitQcDate': '2007-07-25', 'lastUpdatePostDateStruct': {'date': '2021-05-06', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-04-07', 'studyFirstPostDateStruct': {'date': '2007-07-26', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2021-05-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-12-18', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Emotional Reactivity By Pharmacotherapy', 'timeFrame': 'Baseline to 1 month', 'description': 'Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.'}, {'measure': 'Emotional Reactivity By Pharmacotherapy Moderated by DRD2 A1 Allele', 'timeFrame': 'Baseline to 1 month', 'description': 'The emotional reactivity (ORB EMG) of smokers during cessation will be moderated by genotype. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.'}], 'secondaryOutcomes': [{'measure': 'Smoking Abstinence at 3 Months', 'timeFrame': 'Baseline to 3 months', 'description': 'Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.'}, {'measure': 'Smoking Abstinence at 3 Months by DRD2 A1 Allele', 'timeFrame': 'Baseline to 3 Month', 'description': 'Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.'}, {'measure': 'Smoking Abstinence at 6 Months', 'timeFrame': 'Abstinence at 6 Months ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)', 'description': 'Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.'}, {'measure': 'Abstinence at 6 Months by DRD2 A1 Allele', 'timeFrame': 'Baseline to 6 Month ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)', 'description': 'Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.'}, {'measure': 'Symptoms of Nicotine Withdrawal Using the Wisconsin Smoking Withdrawal Scale (WSWS)', 'timeFrame': 'Baseline to 8 months', 'description': 'Symptoms of nicotine withdrawal measured using Wisconsin Smoking Withdrawal Scale (WSWS). The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). A single value was estimated by averaging within the specific time interval. Higher values represent worse outcome. The average value was estimated from Baseline to 8 months'}, {'measure': 'Symptoms of Nicotine Withdrawal and Negative Affect Using Positive and Negative Affect Scale (PANAS)', 'timeFrame': 'Baseline to 8 months', 'description': 'Symptoms of nicotine withdrawal and negative affect were measured using the Positive and Negative Affect Scale (PANAS). The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The average value was estimated from Baseline to 8 months'}, {'measure': 'Symptoms of Depression Using the Center for Epidemiologic Studies Depression Scale (CES-D)', 'timeFrame': 'Baseline to 8 months', 'description': 'Symptoms of nicotine withdrawal measured using Center for Epidemiologic Studies Depression Scale (CES-D). Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The average value was estimated from Baseline to 8 months'}, {'measure': 'Measures of Smoking Satisfaction and Psychological Reward Using the Modified Cigarette Evaluation Questionnaire (mCEQ) Subscales', 'timeFrame': 'Baseline to 8 months', 'description': 'Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items.'}, {'measure': 'Skin Conductance Response', 'timeFrame': 'Baseline to 1 month', 'description': 'Skin conductance response (SCR) amplitude measured by placing an electrodermal response transducer on the fore and ring fingers of the participants non-dominant hand, and heart rate (HR) was collected by placing a photoelectric pulse plethysmogram transducer on the middle finger of the participants non-dominant hand, during the presentation of emotionally valent stimuli (positive, negative, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.'}, {'measure': 'Heart Rate Response', 'timeFrame': 'Baseline to 1 month', 'description': 'Heart Rate Response. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Pharmacogenetics', 'Emotional Reactivity', 'Smoking Cessation Counseling', 'Smoking', 'Bupropion', 'Wellbutrin', 'Wellbutrin SR', 'Zyban', 'Varenicline', 'Chantix', 'Placebo'], 'conditions': ['Tobacco Use Disorder', 'Smoking Cessation']}, 'referencesModule': {'references': [{'pmid': '22571920', 'type': 'BACKGROUND', 'citation': 'Cui Y, Robinson JD, Versace F, Lam CY, Minnix JA, Karam-Hage M, Dani JA, Kosten TR, Wetter DW, Brown VL, Cinciripini PM. Differential cigarette-related startle cue reactivity among light, moderate, and heavy smokers. Addict Behav. 2012 Aug;37(8):885-9. doi: 10.1016/j.addbeh.2012.02.003. Epub 2012 Feb 15.'}, {'pmid': '23060019', 'type': 'BACKGROUND', 'citation': 'Cui Y, Versace F, Engelmann JM, Minnix JA, Robinson JD, Lam CY, Karam-Hage M, Brown VL, Wetter DW, Dani JA, Kosten TR, Cinciripini PM. Alpha oscillations in response to affective and cigarette-related stimuli in smokers. Nicotine Tob Res. 2013 May;15(5):917-24. doi: 10.1093/ntr/nts209. Epub 2012 Oct 11.'}, {'pmid': '25621416', 'type': 'BACKGROUND', 'citation': "Cui Y, Robinson JD, Engelmann JM, Lam CY, Minnix JA, Karam-Hage M, Wetter DW, Dani JA, Kosten TR, Cinciripini PM. Reinforcement sensitivity underlying treatment-seeking smokers' affect, smoking reinforcement motives, and affective responses. Psychol Addict Behav. 2015 Jun;29(2):300-311. doi: 10.1037/adb0000050. Epub 2015 Jan 26."}, {'pmid': '29223599', 'type': 'BACKGROUND', 'citation': 'Cui Y, Engelmann JM, Xian J, Minnix JA, Lam CY, Karam-Hage M, Cinciripini PM, Robinson JD. Pharmacological intervention and abstinence in smokers undergoing cessation treatment: A psychophysiological study. Int J Psychophysiol. 2018 Jan;123:25-34. doi: 10.1016/j.ijpsycho.2017.12.001. Epub 2017 Dec 6.'}, {'pmid': '23643564', 'type': 'BACKGROUND', 'citation': 'Minnix JA, Versace F, Robinson JD, Lam CY, Engelmann JM, Cui Y, Brown VL, Cinciripini PM. The late positive potential (LPP) in response to varying types of emotional and cigarette stimuli in smokers: a content comparison. Int J Psychophysiol. 2013 Jul;89(1):18-25. doi: 10.1016/j.ijpsycho.2013.04.019. Epub 2013 May 2.'}, {'pmid': '24065931', 'type': 'BACKGROUND', 'citation': 'Robinson JD, Versace F, Lam CY, Minnix JA, Engelmann JM, Cui Y, Karam-Hage M, Shete SS, Tomlinson GE, Chen TT, Wetter DW, Green CE, Cinciripini PM. The CHRNA3 rs578776 Variant is Associated with an Intrinsic Reward Sensitivity Deficit in Smokers. Front Psychiatry. 2013 Sep 23;4:114. doi: 10.3389/fpsyt.2013.00114. eCollection 2013.'}, {'pmid': '21182573', 'type': 'BACKGROUND', 'citation': 'Versace F, Minnix JA, Robinson JD, Lam CY, Brown VL, Cinciripini PM. Brain reactivity to emotional, neutral and cigarette-related stimuli in smokers. Addict Biol. 2011 Apr;16(2):296-307. doi: 10.1111/j.1369-1600.2010.00273.x. Epub 2010 Dec 23.'}, {'pmid': '21967530', 'type': 'BACKGROUND', 'citation': 'Versace F, Lam CY, Engelmann JM, Robinson JD, Minnix JA, Brown VL, Cinciripini PM. Beyond cue reactivity: blunted brain responses to pleasant stimuli predict long-term smoking abstinence. Addict Biol. 2012 Nov;17(6):991-1000. doi: 10.1111/j.1369-1600.2011.00372.x. Epub 2011 Oct 4.'}, {'pmid': '24376278', 'type': 'BACKGROUND', 'citation': 'Versace F, Engelmann JM, Robinson JD, Jackson EF, Green CE, Lam CY, Minnix JA, Karam-Hage MA, Brown VL, Wetter DW, Cinciripini PM. Prequit fMRI responses to pleasant cues and cigarette-related cues predict smoking cessation outcome. Nicotine Tob Res. 2014 Jun;16(6):697-708. doi: 10.1093/ntr/ntt214. Epub 2013 Dec 27.'}, {'pmid': '25787146', 'type': 'BACKGROUND', 'citation': 'Meyer MJ, Coull BA, Versace F, Cinciripini P, Morris JS. Bayesian function-on-function regression for multilevel functional data. Biometrics. 2015 Sep;71(3):563-74. doi: 10.1111/biom.12299. Epub 2015 Mar 18.'}, {'pmid': '30057352', 'type': 'BACKGROUND', 'citation': 'Zhu H, Versace F, Cinciripini PM, Rausch P, Morris JS. Robust and Gaussian spatial functional regression models for analysis of event-related potentials. Neuroimage. 2018 Nov 1;181:501-512. doi: 10.1016/j.neuroimage.2018.07.006. Epub 2018 Jul 6.'}, {'pmid': '28275830', 'type': 'BACKGROUND', 'citation': 'Cinciripini PM, Green CE, Robinson JD, Karam-Hage M, Engelmann JM, Minnix JA, Wetter DW, Versace F. Benefits of varenicline vs. bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment. Psychopharmacology (Berl). 2017 Jun;234(11):1769-1779. doi: 10.1007/s00213-017-4580-2. Epub 2017 Mar 8.'}, {'pmid': '37230961', 'type': 'DERIVED', 'citation': 'Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023 May 24;5(5):CD000031. doi: 10.1002/14651858.CD000031.pub6.'}, {'pmid': '37142273', 'type': 'DERIVED', 'citation': 'Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.'}, {'pmid': '23536105', 'type': 'DERIVED', 'citation': 'Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, Brown VL, Engelmann JM, Wetter DW. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013 May;70(5):522-33. doi: 10.1001/jamapsychiatry.2013.678.'}, {'pmid': '22097928', 'type': 'DERIVED', 'citation': 'Versace F, Engelmann JM, Jackson EF, Costa VD, Robinson JD, Lam CY, Minnix JA, Brown VL, Wetter DW, Cinciripini PM. Do brain responses to emotional images and cigarette cues differ? An fMRI study in smokers. Eur J Neurosci. 2011 Dec;34(12):2054-63. doi: 10.1111/j.1460-9568.2011.07915.x. Epub 2011 Nov 20.'}], 'seeAlsoLinks': [{'url': 'http://www.mdanderson.org', 'label': 'University of Texas MD Anderson Cancer Center Website'}]}, 'descriptionModule': {'briefSummary': 'The goals of this placebo-controlled randomized clinical trial were to evaluate the differences in emotional reactivity (peak startle response to affective stimuli) during a cessation attempt among smokers treated with bupropion, varenicline, or placebo, and to determine if these differences were moderated by genotype.', 'detailedDescription': 'Bupropion and Varenicline are smoking cessation aids that may help people to quit smoking.\n\nDuring the orientation visit, the study will be explained to you and you will be given an opportunity to ask, and have answered, any questions you may have. You will also be asked to give a buccal (cheek cell) sample for genetic analysis. This session will last about 1.5 hours.\n\nDuring the screening visit, you will be asked questions about your health, medication use, smoking history, and tobacco use. You will be asked about any current or past feelings of depression. Also, a small blood sample will be drawn (about 2 tablespoons) from your upper arm for a liver and kidney function test and a saliva sample will be collected to measure whether you are smoking. Women who are able to have children must have a negative urine pregnancy test. This session will last about 2.5 hours.\n\nIf you are eligible to take part in the study, you will be randomly assigned (as in the toss of a coin) to one of three treatment groups. Participants in the first group will receive Bupropion. Participants in the second group will receive Varenicline. Participants in the third group will receive a placebo. A placebo is a substance that looks like the study drug but which has no active ingredients. You will have an equal chance of being assigned to the Bupropion, Varenicline, or placebo treatment group. Neither you nor your counselor will know to which group you were assigned.\n\nAll participants will take study pills (either Bupropion, Varenicline, or placebo) by mouth for 12 weeks. The dose of study medication may or may not change during the study. You will be responsible for returning any unused, used, or partly used study medication bottles to a study staff member.\n\nAll participants will receive smoking cessation counseling to help them quit smoking, in the form of both in-person and telephone counseling sessions. Some of the counseling sessions may be videotaped or audio-taped. The videotapes will be used to help the investigators make sure that the counselors are following the correct procedures and will be erased within one year following your completion of the study. No one but the study investigators or those delegated by the study investigators will be allowed to view the tapes and the identity of the participants will be kept strictly confidential. Staff that may be given permission to view the tapes include project staff, consultants that review and rate how well the study counselors follow guidelines, and/or consultants that review how well the assessments are given.\n\nYou will need to come to the Behavioral Science Research Clinic at M. D. Anderson for 9 clinic visits over an 8-month period. You will receive 5 telephone calls from the study staff (while in treatment and during follow-up) to check on your progress in quitting smoking.\n\nYou will complete your first lab evaluation session (baseline) before any treatment begins (while you are still smoking). Immediately after the baseline lab session (on the same day), you will begin to receive counseling to quit smoking. You will begin taking one of the 3 study medications (Bupropion, Varenicline, or placebo) the next morning.\n\nThere will be 3 lab sessions, during which you will be asked to complete questionnaires about your mood and feelings (about 30 minutes total). Also, you will give a breath sample by blowing air into a small tube. This sample shows how much you have smoked. In each session you will be asked to watch slides and listen to a series of tones through earphones. The slides will include pictures of people, nature scenes, and artwork. Slides showing victims of car crashes, medical procedures, and nude people will also be shown. You will be shown examples of these slides before beginning the procedure and given the opportunity to withdraw from the study. During the lab sessions, your heart rate, brain electrical activity (EEG), skin sweating, and muscle tension will be monitored. To do this, small sensors will be placed on the fingers, arms, scalp and face. You should not drink more than 2 cups of coffee or other caffeine drinks at least 2.5 hours before each session.\n\nDuring the first counseling visit, you will set a quit date for stopping smoking about 2 weeks after starting your study medication. You are asked not to quit smoking before the set quit date. After your quit date, you are asked to stay smoke free. You are asked to attend all your sessions whether you are smoking or not. All participants will receive smoking cessation counseling in the form of both in-person and telephone counseling sessions. The purpose of these visits will be to prepare you for quitting and to check the effects of the study medication on your attempt to stop smoking.\n\nAt each of your clinic visits, your blood pressure will be taken and you will be asked to blow air through a carbon monoxide (CO) measuring device. CO is a gas that is found in higher levels among cigarette smokers. At several visits you will be asked to provide a saliva sample to check for cotinine, a chemical produced by the breakdown of nicotine during smoking. You will be asked to give a saliva sample in a collection tube. Like the CO test, this test will help researchers measure how much you are smoking.\n\nAt your visits you will be asked questions about your smoking behavior. You will also be asked questions about your health and medical condition, and about any medications you are taking. You will be asked to complete a daily diary on cigarette smoking and drug dosing.\n\nYou will also be asked to mail saliva samples back to the clinic at least two times after stopping the medication. This will allow researchers to check on your smoking status.\n\nYour total participation in this study will last about 8 months. This will include a 3-month and 6-month follow-up visit after your scheduled quit date. If the study staff is not able to reach you by phone, mail, or the information provided by your contacts, they may try to locate you through telephone directory assistance (411) or internet search sources (for example, Google or Yahoo!), which use information from the public domain (meaning everyone has access to it). If the study staff is still unable to find you, they may use a locator service such as Transunion or the National Change of Address (NCOA) database maintained by the United States Postal Service, as a last resort. Transunion uses magazine subscriptions and credit applications to find new addresses, and the NCOA uses the Change of Address cards filed with the post office when a person moves and requests their mail be forwarded to a new address. If the study staff has to use either of these services, they would only disclose your name and last known address.\n\nAt the end of the study, you will be able to ask additional questions about the results of the study and about procedures you have experienced during the study. Additionally, you will be able to sign up to receive a copy of the paper that will be written at the completion of the study.\n\nThis is an investigational study. Up to 375 smokers will take part in this study. All will be enrolled at MD Anderson.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Age: 18-65 years old\n2. Smoking: \\>/= 5 cigarettes per day within the 2 months preceding the screening visit and expired CO greater than or equal to 6 ppm.\n3. Able to follow verbal and written instructions in English and complete all aspects of the study\n4. Have an address and home telephone number where they may be reached\n5. Provide informed consent and agree to all assessments and study procedures\n6. Be the only participant in their household\n\nExclusion Criteria:\n\n1. Within the month immediately preceding the screening visit; use of any form of tobacco product other than cigarettes on 3 or more days within a week only if the individual refuses to refrain from non-cigarette tobacco use during the course of this study\n2. Within the month immediately preceding the screening visit; use of marijuana in any form on 3 or more days within a week\n3. Within the two weeks immediately preceding the screening visit, involvement on more than 3 days in any formal smoking cessation activities\n4. Current visual or auditory problems that in the opinion of the investigator would interfere with the completion of study assessments\n5. Treatment on a continuous basis within 2 weeks before the screening visit: any contraindicated medication for Varenicline or Bupropion.\n6. Uncontrolled hypertension or other major contraindications for Bupropion or Varenicline.\n7. Severe renal impairment (CR Clearance \\<30 ml/min/1.73 m2).\n8. Laboratory evaluations outside normal limits and of potential clinical significance in the opinion of the investigator\n9. Meet current criteria for psychiatric disorders or substance abuse as assessed by the MINI for items A, B, D, I, J, K, L, M and N, including a past manic or hypomanic episode as well as a lifetime psychotic disorder.\n10. Subject rated as moderate to high on suicidality as assessed by the MINI.\n11. Psychiatric hospitalization within 1 year of screening date.\n12. A positive urine pregnancy test during the screening period. Women who are two years post menopausal, one year post-tubal ligation, or who have had a partial or full hysterectomy will not be subject to a urine pregnancy test.\n13. Pregnant, breast-feeding, or of childbearing potential who is not protected by a medically acceptable, effective method of birth control while enrolled in the study\n14. Use of Varenicline or Bupropion within two weeks before the screening visit.\n15. History of hypersensitivity or allergic reaction to Varenicline, tricyclic antidepressant, Bupropion (Wellbutrin, Zyban) or similar chemical classes or any component of these formulations.\n16. Subject considered by the investigator as unsuitable candidate for receipt of an investigational drug, or unstable to be followed up throughout the entire duration of the study.'}, 'identificationModule': {'nctId': 'NCT00507728', 'briefTitle': 'Pharmacogenetics, Emotional Reactivity and Smoking', 'organization': {'class': 'OTHER', 'fullName': 'M.D. Anderson Cancer Center'}, 'officialTitle': 'Pharmacogenetics, Emotional Reactivity and Smoking', 'orgStudyIdInfo': {'id': '2003-1024'}, 'secondaryIdInfos': [{'id': '1R01DA017073', 'link': 'https://reporter.nih.gov/quickSearch/1R01DA017073', 'type': 'NIH'}, {'id': 'NCI-2012-02108', 'type': 'REGISTRY', 'domain': 'NCI CTRP'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Bupropion', 'description': 'Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).', 'interventionNames': ['Drug: Bupropion', 'Behavioral: Smoking Cessation Counseling']}, {'type': 'EXPERIMENTAL', 'label': 'Varenicline', 'description': 'Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).', 'interventionNames': ['Drug: Varenicline', 'Behavioral: Smoking Cessation Counseling']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo by mouth for 12 weeks.', 'interventionNames': ['Drug: Placebo', 'Behavioral: Smoking Cessation Counseling']}], 'interventions': [{'name': 'Bupropion', 'type': 'DRUG', 'otherNames': ['Wellbutrin', 'Wellbutrin SR', 'Zyban'], 'description': 'Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)', 'armGroupLabels': ['Bupropion']}, {'name': 'Varenicline', 'type': 'DRUG', 'otherNames': ['Chantix'], 'description': 'Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)', 'armGroupLabels': ['Varenicline']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo by mouth for 12 weeks.', 'armGroupLabels': ['Placebo']}, {'name': 'Smoking Cessation Counseling', 'type': 'BEHAVIORAL', 'description': 'Counseling over 8 months and telephone support calls.', 'armGroupLabels': ['Bupropion', 'Placebo', 'Varenicline']}]}, 'contactsLocationsModule': {'locations': [{'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'University of Texas MD Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}], 'overallOfficials': [{'name': 'Paul Cinciripini, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'M.D. Anderson Cancer Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'M.D. Anderson Cancer Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institutes of Health (NIH)', 'class': 'NIH'}, {'name': 'National Institute on Drug Abuse (NIDA)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}